Crossmark

Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data

Crossref DOI link: https://doi.org/10.1186/s12890-018-0759-5

Published Online: 2019-01-10

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mortimer, Kathleen

Hartmann, Nadine

Chan, Christine

Norman, Heather

Wallace, Laura

Enger, Cheryl
Funding

Funding for this research was provided by:

Boehringer Ingelheim

Optum
License Information

Text and Data Mining valid from 2019-01-10
More Information

Article History

Received: 6 July 2018

Accepted: 4 December 2018

First Online: 10 January 2019

Ethics approval and consent to participate

: This study was approved by the Western Institutional Review Board (WIRB, Study No.: 1178316). This Board found that this research met the requirements for a waiver of consent under 45 CFR 46.116(d), thus no further permissions were required to utilize the datasets for this study.

: Not applicable.

: NH and LW are employees for Boehringer Ingelheim., CE and HN are employees of Optum. KM and CC were employees of Optum at the time this study was conducted. The authors have no conflicts of interest to report.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.